Saturday, October 26, 2019 6:38:16 AM
Gary, I am no expert too, for Direct as the name indicated, the Dendritic cells were not coached or educated to recognize the antigens yet. The cells picked up the antigens of the tumors after “Directly” injected into the tumors. The tumors can be any “types” of solid tumors. The tumors can be “anywhere” in the body.
Oh and these were the secret ingredients that I forgot to mention.
After the process of leukapheresis, the blood was frozen and fedexed to Cognate. At Cognate, they processed the blood through very strict and proprietary procedures to get specific Dendritic Cells which were young and powerful. These processes were patented. These dendritic cells when injected to patients tumors, would mobilize T-cells to recognize tumors antigens or DNAs. Tumors could not hide by pretending they were “friends” anymore. Their existence became so visible in front of T-cells. T-cells attacked the cancers immediately since they are army inside our body. When the wars inside the body happened, the patients felt “fever” or flu like symptoms. With method B of Direct, out of 21 stage 4 patients, 18 were stable as soon as 8 weeks. Wow.
Oh and these were the secret ingredients that I forgot to mention.
After the process of leukapheresis, the blood was frozen and fedexed to Cognate. At Cognate, they processed the blood through very strict and proprietary procedures to get specific Dendritic Cells which were young and powerful. These processes were patented. These dendritic cells when injected to patients tumors, would mobilize T-cells to recognize tumors antigens or DNAs. Tumors could not hide by pretending they were “friends” anymore. Their existence became so visible in front of T-cells. T-cells attacked the cancers immediately since they are army inside our body. When the wars inside the body happened, the patients felt “fever” or flu like symptoms. With method B of Direct, out of 21 stage 4 patients, 18 were stable as soon as 8 weeks. Wow.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
